Biblos-e Archivo. Repositorio Institucional de la UAM
Publication
Artículo científico (JournalArticle)
Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data
Objectives
To assess the effects of early management of hyperglycaemia with antidiabetic drugs plus
lifestyle intervention compared with lifestyle alone, on microvascular function in adults with
pre-diabetes.
Methods
Trial design: International, multicenter, randomised, partially double-blind, placebo-controlled,
clinical trial.
Participants
Males and females aged 45–74 years with IFG, IGT or IFG+IGT, recruited from primary
care centres in Australia, Austria, Bulgaria, Greece, Kuwait, Poland, Serbia, Spain and
Turkey
Intervention
Participants were randomized to placebo; metformin 1.700 mg/day; linagliptin 5 mg/day or
fixed-dose combination of linagliptin/metformin. All patients were enrolled in a lifestyle intervention
program (diet and physical activity). Drug intervention will last 2 years. Primary Outcome:
composite end-point of diabetic retinopathy estimated by the Early Treatment
Diabetic Retinopathy Study Score, urinary albumin to creatinine ratio, and skin conductance
in feet estimated by the sudomotor index. Secondary outcomes in a subsample include insulin
sensitivity, beta-cell function, biomarkers of inflammation and fatty liver disease, quality
of life, cognitive function, depressive symptoms and endothelial function
Results
One thousand three hundred ninety one individuals with hyperglycaemia were assessed for
eligibility, 424 excluded after screening, 967 allocated to placebo, metformin, linagliptin or to
fixed-dose combination of metformin + linagliptin. A total of 809 people (91.1%) accepted
and initiated the assigned treatment. Study sample after randomization was well balanced
among the four groups. No statistical differences for the main risk factors analysed were
observed between those accepting or rejecting treatment initiation. At baseline prevalence
of diabetic retinopathy was 4.2%, severe neuropathy 5.3% and nephropathy 5.7%.
Conclusions
ePREDICE is the first -randomized clinical trial with the aim to assess effects of different
interventions (lifestyle and pharmacological) on microvascular function in people with prediabetes.
The trial will provide novel data on lifestyle modification combined with glucose
lowering drugs for the prevention of early microvascular complications and diabetes, All the funding or sources of support
received during this specific study: - European
Commission, FP7 EC-GA No. 279074 - Merck-
Serono, Germany - Boeringher Ingelheim,
Germany (IIS Program. Grant number 1218.166) -
Instituto de Salud Carlos III, Spain PI11/01653